Search results for " Immunology and Allergy"

showing 10 items of 141 documents

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

2015

Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8…

Cell typeImmunologySettore MED/08 - Anatomia PatologicaangiogenesisB non-Hodgkin lymphomahemic and lymphatic diseasesmedicineIL-17AImmunology and Allergytumor immunologyCXCL13B-cell lymphomaangiogenesis; B non-Hodgkin lymphoma; GC B cells; IL-17A; IL-17A receptor; tumor immunology; Immunology and Allergy; Oncology; ImmunologyB cellOriginal ResearchSevere combined immunodeficiencybusiness.industryIL-17A receptorGerminal centerInterleukinangiogenesimedicine.diseaseMolecular biologyGC B cellmedicine.anatomical_structureOncologyCell cultureImmunologyGC B cellsbusiness
researchProduct

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

2015

Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load ( 50 copies/ml) after initial s…

CyclopropanesMaleEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body WeightHIV InfectionsOverweight10234 Clinic for Infectious DiseasesCohort Studieschemistry.chemical_compoundAntiretroviral Therapy Highly ActiveImmunology and AllergyHIV InfectionImmunological responsevirus diseasesVirological responseMiddle AgedViral LoadReverse Transcriptase InhibitorTreatment OutcomeInfectious DiseasesAlkynesCohort2723 Immunology and AllergyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.symptomViral loadCohort studyHumanBenzoxazineAdultmedicine.medical_specialtyEfavirenzImmunologyAntiretroviral Therapy610 Medicine & healthRegression AnalysiPharmacokineticsInternal medicinemedicineHumansHighly ActiveObesity2403 Immunologybusiness.industryProportional hazards modelBody WeightHIV2725 Infectious DiseasesEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body Weight; Immunology and Allergy; Immunology; Infectious Diseasesmedicine.diseaseWeightObesityBenzoxazinesCD4 Lymphocyte Countlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]chemistryImmunologyCohort StudieEfavirenzbusiness
researchProduct

CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells

2004

We investigated the membrane localization of CD95 in type I and type II cells, which differ in their ability to recruit and activate caspase-8. We found that CD95 was preferentially located in lipid rafts of type I cells, while it was present both in raft and non-raft plasma membrane sub-domains of type II cells. After stimulation, CD95 located in phospholipid-rich plasma membrane was recruited to lipid rafts in both types of cells. Similarly, CD95 cross-linking resulted in caspase-independent translocation of FADD/MORT1 and caspase-8 to the lipid rafts, which was prevented by a death domain-defective receptor. CD95 internalization was then rapid in type I and delayed in type II cells and s…

Death Domain Receptor Signaling Adaptor ProteinsEndosomeT-Lymphocytesmedia_common.quotation_subjectImmunologyApoptosisReceptors Tumor Necrosis FactorCell LineMembrane MicrodomainsSettore MED/04 - PATOLOGIA GENERALECell Line TumorReceptorsHumansImmunology and Allergyfas ReceptorFADDInternalizationLipid raftLipid raftsDeath domainmedia_commonTumorbiologyVesicleFas receptorEndocytosisCell biologyProtein TransportCholesterolCD95 death-inducing signaling complexCaspasesCD95biology.proteinlipids (amino acids peptides and proteins)biological phenomena cell phenomena and immunityCaspase-8Tumor Necrosis FactorCaspase-8; CD95; Lipid rafts; Apoptosis; Caspases; Cell Line Tumor; Cholesterol; Death Domain Receptor Signaling Adaptor Proteins; Humans; Membrane Microdomains; Protein Binding; Protein Transport; Receptors Tumor Necrosis Factor; T-Lymphocytes; fas Receptor; Endocytosis; Signal Transduction; Immunology and Allergy; ImmunologyProtein BindingSignal TransductionEuropean Journal of Immunology
researchProduct

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells

2012

SummaryMature dendritic cells (DCs) are established as unrivaled antigen-presenting cells (APCs) in the initiation of immune responses, whereas steady-state DCs induce peripheral T cell tolerance. Using various genetic approaches, we depleted CD11c+ DCs in mice and induced autoimmune CNS inflammation. Unexpectedly, mice lacking DCs developed aggravated disease compared to control mice. Furthermore, when we engineered DCs to present a CNS-associated autoantigen in an induced manner, we found robust tolerance that prevented disease, which coincided with an upregulation of the PD-1 receptor on antigen-specific T cells. Additionally, we showed that PD-1 was necessary for DC-mediated induction o…

Encephalomyelitis Autoimmune ExperimentalT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationCD11cAutoimmunity610 Medicine & healthchemical and pharmacologic phenomenaBiologymedicine.disease_causeAutoantigensT-Lymphocytes RegulatoryB7-H1 AntigenAutoimmunityImmune toleranceMiceImmune systemDownregulation and upregulationImmune TolerancemedicineAnimalsImmunology and AllergyReceptorMice KnockoutAntigen Presentation2403 Immunologyhemic and immune systemsDendritic Cells2725 Infectious DiseasesTh1 CellsCD11c AntigenMice Inbred C57BLInfectious Diseasesmedicine.anatomical_structure10032 Clinic for Oncology and HematologyImmunology2723 Immunology and AllergyTh17 CellsImmunity
researchProduct

AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS

2000

H-IL-6 is a hybrid protein constructed to contain IL-6 and its soluble receptor linked by a flexible peptide chain. Here we show that H-IL-6 strongly enhances proliferation of human CD34(+)cells in serum-free liquid culture, and that the majority of the cells generated belong to the erythroid lineage, being positive for the marker Glycophorin A. Conversely, H-IL-6 does not increase the number of myeloid, CD13-positive cells. Comparable effects are observed on progenitors from cord blood and adult peripheral blood. Therefore, H-IL-6 triggers an erythroid-inducing signal in haematopoietic progenitor cells, independently from erythropoietin (EPO).

ErythrocytesTime FactorsMyeloidCellular differentiationInterleukin 6Antigens CD34BiochemistryCulture Media Serum-FreeSerum-Freehemic and lymphatic diseasesReceptorsLeukocytesImmunology and AllergyErythropoiesisGlycophorinsStem Cell FactorbiologyChemistryCord bloodCell DifferentiationHematologyFetal BloodFlow CytometryEndothelial stem cellHaematopoiesismedicine.anatomical_structureGlycophorinCD34+medicine.drugRecombinant Fusion ProteinsMononuclearImmunologyCD13 AntigensmedicineHumansGlycophorinAntigensProgenitor cellErythropoietinMolecular BiologyInterleukin 3Interleukin-6CD34+; Cord blood; Erythropoiesis; Interleukin 6; Stem cell factor; Antigens CD34; CD13 Antigens; Cell Differentiation; Culture Media Serum-Free; Erythrocytes; Erythropoietin; Fetal Blood; Flow Cytometry; Glycophorin; Hematopoietic Stem Cells; Humans; Interleukin-6; Leukocytes Mononuclear; Peptides; Receptors Interleukin-6; Recombinant Fusion Proteins; Stem Cell Factor; Time Factors; Immunology and Allergy; Immunology; Biochemistry; Hematology; Molecular BiologyHematopoietic Stem CellsReceptors Interleukin-6Molecular biologyCulture MediaErythropoietinLeukocytes Mononuclearbiology.proteinCD34PeptidesCytokine
researchProduct

Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis

2017

BackgroundDysbiosis has been recently demonstrated in patients with ankylosing spondylitis (AS) but its implications in the modulation of intestinal immune responses have never been studied. The aim of this study was to investigate the role of ileal bacteria in modulating local and systemic immune responses in AS.MethodsIleal biopsies were obtained from 50 HLA-B27+ patients with AS and 20 normal subjects. Silver stain was used to visualise bacteria. Ileal expression of tight and adherens junction proteins was investigated by TaqMan real-time (RT)-PCR and immunohistochemistry. Serum levels of lipopolysaccharide (LPS), LPS-binding protein (LPS-BP), intestinal fatty acid-BP (iFABP) and zonulin…

Genetics and Molecular Biology (all)Fatty Acid-Binding ProteinAnkylosing SpondylitisMonocyteBiochemistryMonocytesTransgenic0302 clinical medicineIntestinal MucosaMembrane GlycoproteinsZonulinCadherinsAdherens JunctionUp-RegulationAntigenAcute DiseaseMembrane GlycoproteinRats TransgenicInfectionHumanAnkylosingImmunologyGeneral Biochemistry Genetics and Molecular BiologyArticlePermeabilityTight Junctions03 medical and health sciencesRheumatologyAntigens CDIleumAnti-Bacterial AgentHuman Umbilical Vein Endothelial CellsHumansRNA MessengerEndotheliumProtein PrecursorsAnkylosing SpondylitiBiochemistry Genetics and Molecular Biology (all)BacteriaAnimalmedicine.diseaseDysbiosiSettore MED/16 - Reumatologia030104 developmental biologychemistryCase-Control StudiesImmunologyRatCarrier ProteinsAcute-Phase ProteinsSpondylitis0301 basic medicineLipopolysaccharidesLipopolysaccharideMessengerAcute-Phase ProteinGene Expressionchemistry.chemical_compoundIntestinal mucosaImmunology and AllergyMembrane ProteinHLA-B27 AntigenCaco-2 CellTight junctionTight JunctionAdherens JunctionsIleitisIleitiAnti-Bacterial AgentsCDmedicine.anatomical_structureAnkylosing Spondylitis; Infections; Inflammation; Acute Disease; Acute-Phase Proteins; Adherens Junctions; Animals; Anti-Bacterial Agents; Antigens CD; Bacteria; Caco-2 Cells; Cadherins; Carrier Proteins; Case-Control Studies; Cholera Toxin; Chronic Disease; Dysbiosis; Endothelium; Fatty Acid-Binding Proteins; Gene Expression; HLA-B27 Antigen; Human Umbilical Vein Endothelial Cells; Humans; Ileitis; Ileum; Interleukin-8; Intestinal Mucosa; Junctional Adhesion Molecule A; Lipopolysaccharides; Membrane Glycoproteins; Membrane Proteins; Monocytes; Permeability; RNA Messenger; Rats; Rats Transgenic; Spondylitis Ankylosing; Tight Junctions; Up-Regulationmedicine.symptomCase-Control StudieCholera ToxinHuman Umbilical Vein Endothelial CellLipopolysaccharideInflammationInfectionsFatty Acid-Binding ProteinsAdherens junctionmedicineAnkylosing Spondylitis; Infections; Inflammation; Acute Disease; Acute-Phase Proteins; Adherens Junctions; Animals; Anti-Bacterial Agents; Antigens CD; Bacteria; Caco-2 Cells; Cadherins; Carrier Proteins; Case-Control Studies; Cholera Toxin; Chronic Disease; Dysbiosis; Endothelium; Fatty Acid-Binding Proteins; Gene Expression; HLA-B27 Antigen; Human Umbilical Vein Endothelial Cells; Humans; Ileitis; Ileum; Interleukin-8; Intestinal Mucosa; Junctional Adhesion Molecule A; Lipopolysaccharides; Membrane Glycoproteins; Membrane Proteins; Monocytes; Permeability; RNA Messenger; Rats; Rats Transgenic; Spondylitis Ankylosing; Tight Junctions; Up-Regulation; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)AnimalsSpondylitis AnkylosingAntigensSpondyliti030203 arthritis & rheumatologyInflammationHaptoglobinsbusiness.industryMonocyteInterleukin-8Membrane ProteinsRatsJunctional Adhesion Molecule AChronic DiseaseCadherinDysbiosisRNACaco-2 CellsCarrier ProteinbusinessDysbiosis
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.

2017

Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment of inflammatory bowel disease (IBD)1 following the good clinical responses reported by clinical trials for both Crohn's disease2 and ulcerative colitis.3 However, the effects of VDZ on extraintestinal manifestations were not reported in these trials, and the ‘real life’ experience is still limited. On these premises, we read with interest the recent work by Varkas et al 4 reporting a series of five patients with IBD who were treated with VDZ and promptly developed new onset or exacerbation of spondyloarthritis (SpA), irrespective of the response to treatment on intestinal symptoms. Although the hypothe…

Genetics and Molecular Biology (all)medicine.medical_specialtyExacerbationT CellImmunologyPremisesAntibodies Monoclonal HumanizedBiochemistryInflammatory bowel diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyNew onsetVedolizumab03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSpondylarthritismedicineImmunology and AllergyHumansIn patientSacroiliitis030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)business.industrymedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesRheumatologyTreatmentClinical trial030211 gastroenterology & hepatologySpondyloarthritis; T Cells; Treatment; Rheumatology; Immunology and Allergy; Immunology; Biochemistry Genetics and Molecular Biology (all)Spondyloarthritibusinessmedicine.drugAnnals of the rheumatic diseases
researchProduct

EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arte…

2010

EULAR/PRINTO/PRES Objectives To validate the previously proposed classification criteria for Henoch-Schonlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) and c-Takayasu arteritis (c-TA).Methods Step 1: retrospective/prospective webdata collection for children with HSP, c-PAN, c-WG and c-TA with age at diagnosis <= 18 years. Step 2: blinded classification by consensus panel of a representative sample of 280 cases. Step 3: statistical (sensitivity, specificity, area under the curve and.-agreement) and nominal group technique consensus evaluations.Results 827 patients with HSP, 150 with c-PAN, 60 with c-WG, 87 with c-TA and 52 with c-other were compar…

Genetics and Molecular Biology (all)myalgiaVasculitismedicine.medical_specialtyHenoch-Schonlein purpuraAdolescentIgA VasculitisClassification criteriaInternational CooperationImmunologychildhood polyarteritis nodosaBiochemistryGeneral Biochemistry Genetics and Molecular BiologyRheumatologyhemic and lymphatic diseasesTerminology as TopicSchoenlein-HenochmedicineHumansImmunology and Allergycardiovascular diseasesArteritisChildPurpurac-Wegener granulomatosisAdolescent; Child; Epidemiologic Methods; Granulomatosis with Polyangiitis; Humans; International Cooperation; Polyarteritis Nodosa; Purpura Schoenlein-Henoch; Takayasu Arteritis; Terminology as Topic; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all); Immunology and Allergycriteria; children; Henoch-Schönlein purpura; childhood polyarteritis nodosa; Wegener granulomatosis; Takayasu arteritis; EULAR; PRINTO; PRESPolyarteritis nodosabusiness.industryGranulomatosis with Polyangiitismedicine.diseaseTakayasu ArteritisDermatologyPolyarteritis NodosaSurgeryHenoch-Schönlein purpuraIgA vasculitisSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAmedicine.symptomEpidemiologic MethodsGranulomatosis with polyangiitisVasculitisbusinessRheumatismc-Takayasu arteriti
researchProduct

The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

2017

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Latvian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsDisease statusHealth StatusHealth-related quality of lifeArthritisDisease status; Functional ability; Health-related quality of life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; ImmunologyDisability Evaluation0302 clinical medicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPrognosisChild PreschoollanguageFemalemedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsImmunologyMultidimensional assessment03 medical and health sciencesRheumatologyPredictive Value of Tests030225 pediatricsInternal medicinemedicineJuvenileHumansPatient Reported Outcome MeasuresValidation Studies030203 arthritis & rheumatologyHealth related quality of lifeCultural Characteristicsbusiness.industryLatvianReproducibility of ResultsTranslatingJuvenile idiopathic arthritismedicine.diseaseLatviaFunctional abilityRheumatologylanguage.human_languageArthritis JuvenileCase-Control StudiesQuality of LifebusinessRheumatology international
researchProduct